236 related articles for article (PubMed ID: 21450833)
1. Pseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropism.
Muik A; Kneiske I; Werbizki M; Wilflingseder D; Giroglou T; Ebert O; Kraft A; Dietrich U; Zimmer G; Momma S; von Laer D
J Virol; 2011 Jun; 85(11):5679-84. PubMed ID: 21450833
[TBL] [Abstract][Full Text] [Related]
2. Xenoantigen-Dependent Complement-Mediated Neutralization of Lymphocytic Choriomeningitis Virus Glycoprotein-Pseudotyped Vesicular Stomatitis Virus in Human Serum.
Pipperger L; Koske I; Wild N; Müllauer B; Krenn D; Stoiber H; Wollmann G; Kimpel J; von Laer D; Bánki Z
J Virol; 2019 Sep; 93(18):. PubMed ID: 31243134
[TBL] [Abstract][Full Text] [Related]
3. Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors.
Wollmann G; Drokhlyansky E; Davis JN; Cepko C; van den Pol AN
J Virol; 2015 Jul; 89(13):6711-24. PubMed ID: 25878115
[TBL] [Abstract][Full Text] [Related]
4. Understanding and altering cell tropism of vesicular stomatitis virus.
Hastie E; Cataldi M; Marriott I; Grdzelishvili VZ
Virus Res; 2013 Sep; 176(1-2):16-32. PubMed ID: 23796410
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.
Koske I; Rössler A; Pipperger L; Petersson M; Barnstorf I; Kimpel J; Tripp CH; Stoitzner P; Bánki Z; von Laer D
Int J Cancer; 2019 Oct; 145(7):1958-1969. PubMed ID: 30972741
[TBL] [Abstract][Full Text] [Related]
6. Selective transduction of malignant glioma by lentiviral vectors pseudotyped with lymphocytic choriomeningitis virus glycoproteins.
Miletic H; Fischer YH; Neumann H; Hans V; Stenzel W; Giroglou T; Hermann M; Deckert M; Von Laer D
Hum Gene Ther; 2004 Nov; 15(11):1091-100. PubMed ID: 15610609
[TBL] [Abstract][Full Text] [Related]
7. Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: generation, concentration, and broad host range.
Beyer WR; Westphal M; Ostertag W; von Laer D
J Virol; 2002 Feb; 76(3):1488-95. PubMed ID: 11773421
[TBL] [Abstract][Full Text] [Related]
8. Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency.
Muik A; Stubbert LJ; Jahedi RZ; Geiβ Y; Kimpel J; Dold C; Tober R; Volk A; Klein S; Dietrich U; Yadollahi B; Falls T; Miletic H; Stojdl D; Bell JC; von Laer D
Cancer Res; 2014 Jul; 74(13):3567-78. PubMed ID: 24812275
[TBL] [Abstract][Full Text] [Related]
9. Vesicular Stomatitis Virus (VSV) G Glycoprotein Can Be Modified to Create a Her2/Neu-Targeted VSV That Eliminates Large Implanted Mammary Tumors.
Gao Y; Bergman I
J Virol; 2023 Jun; 97(6):e0037223. PubMed ID: 37199666
[TBL] [Abstract][Full Text] [Related]
10. Attenuation of vesicular stomatitis virus infection of brain using antiviral drugs and an adeno-associated virus-interferon vector.
Wollmann G; Paglino JC; Maloney PR; Ahmadi SA; van den Pol AN
Virology; 2015 Jan; 475():1-14. PubMed ID: 25462341
[TBL] [Abstract][Full Text] [Related]
11. Chikungunya-vesicular stomatitis chimeric virus targets and eliminates brain tumors.
Zhang X; Mao G; van den Pol AN
Virology; 2018 Sep; 522():244-259. PubMed ID: 30055515
[TBL] [Abstract][Full Text] [Related]
12. Lymphocytic choriomeningitis virus. VIII. Reciprocal formation of pseudotypes with vesicular stomatitis virus.
Bruns M; Lehmann-Grube F
Virology; 1984 Aug; 137(1):49-57. PubMed ID: 6089420
[TBL] [Abstract][Full Text] [Related]
13. Normal brain cells contribute to the bystander effect in suicide gene therapy of malignant glioma.
Miletic H; Fischer YH; Giroglou T; Rueger MA; Winkeler A; Li H; Himmelreich U; Stenzel W; Jacobs AH; von Laer D
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6761-8. PubMed ID: 18006778
[TBL] [Abstract][Full Text] [Related]
14. Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent.
Heiber JF; Barber GN
J Virol; 2011 Oct; 85(20):10440-50. PubMed ID: 21813611
[TBL] [Abstract][Full Text] [Related]
15. VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications.
Tober R; Banki Z; Egerer L; Muik A; Behmüller S; Kreppel F; Greczmiel U; Oxenius A; von Laer D; Kimpel J
J Virol; 2014 May; 88(9):4897-907. PubMed ID: 24554655
[TBL] [Abstract][Full Text] [Related]
16. Neuroattenuation of vesicular stomatitis virus through picornaviral internal ribosome entry sites.
Ammayappan A; Nace R; Peng KW; Russell SJ
J Virol; 2013 Mar; 87(6):3217-28. PubMed ID: 23283963
[TBL] [Abstract][Full Text] [Related]
17. The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer.
Schreiber LM; Urbiola C; Das K; Spiesschaert B; Kimpel J; Heinemann F; Stierstorfer B; Müller P; Petersson M; Erlmann P; von Laer D; Wollmann G
Br J Cancer; 2019 Oct; 121(8):647-658. PubMed ID: 31530903
[TBL] [Abstract][Full Text] [Related]
18. Retargeting Oncolytic Vesicular Stomatitis Virus to Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia.
Betancourt D; Ramos JC; Barber GN
J Virol; 2015 Dec; 89(23):11786-800. PubMed ID: 26378177
[TBL] [Abstract][Full Text] [Related]
19. Differential infection of murine and human dendritic cell subsets by oncolytic vesicular stomatitis virus variants.
Pipperger L; Riepler L; Kimpel J; Siller A; Stoitzner P; Bánki Z; von Laer D
Oncoimmunology; 2021; 10(1):1959140. PubMed ID: 34484872
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors.
Porosnicu M; Quinson AM; Crossley K; Luecke S; Lauer UM
Future Oncol; 2022 Aug; 18(24):2627-2638. PubMed ID: 35699077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
